Atripla Sales Data
| Rank 15 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Atripla U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 15 ( 1) |
$679,418 | 0.36% | 428 | -0.23% |
| Q3 2013 | 14 (1) |
$676,995 | -5.24% | 429 | -7.74% |
| Q2 2013 | 13 | $714,464 | -1.24% | 465 | -2.92% |
| Q1 2013 | 13 | $723,408 | 4.03% | 479 | -0.83% |
| Q4 2012 | 13 (1) |
$695,411 | 0.46% | 483 | 1.68% |
| Q3 2012 | 12 ( 4) |
$692,246 | 1.34% | 475 | -0.42% |
| Q2 2012 | 16 (1) |
$683,070 | -1.70% | 477 | -2.45% |
| Q1 2012 | 17 (2) |
$694,901 | 5.61% | 489 | 1.45% |
| Q4 2011 | 19 (1) |
$657,962 | 4.92% | 482 | 4.78% |
| Q3 2011 | 20 (2) |
$627,084 | 0.42% | 460 | 0.88% |
| Q2 2011 | 22 | $624,469 | 6.31% | 456 | 1.79% |
| Q1 2011 | 22 | $587,422 | n/a | 448 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
